FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2141561613> ?p ?o ?g. }

• W2141561613 endingPage "500" @default.
• W2141561613 startingPage "493" @default.
• W2141561613 abstract "Background The aim of this study was to compare safety and efficacy of the association of busulfan with cyclophosphamide (BuCy2) versus busulfan and fludarabine (BuFlu) as a conditioning regimen in allogeneic hematopoietic progenitor cell transplantation (allo-HPCT) in patients with acute myeloid leukemia (AML). Patients and Methods A total of 65 consecutive patients who received an allo-HPCT from Human Leucocyte Antigen-matched sibling donors were analyzed. The conditioning was BuCy2 in 48 patients and BuFlu in 17 patients. Results There were no significant differences between the 2 cohorts in hematological engraftment, incidence of extrahematological toxicities, and acute graft versus host disease (GVHD). The incidence of chronic GVHD was 34% in the BuCy2 group versus 57% in the BuFlu group (P = .03). Transplant-related mortality was 17% (8 patients) in the BuCy2 group versus 0 in the BuFlu arm. Disease-related mortality was similar in the whole study population; in high-risk AML patients it was 11% in the BuCy2 group and 19% in the BuFlu group (P = .015). The probability of disease-free and event-free survival at 2 years was, respectively, 70% and 60% in the BuCy2 group and 59% and 58% in the BuFlu group (P = .06 and P = not significant [ns]). The probability of overall survival at 2 years was 71% in the BuCy2 group and 63% in the BuFlu group (P = ns), and in the high-risk group it was 83% and 67% in the BuCy2 and BuFlu group, respectively (P = ns). Conclusion BuFlu is well tolerated and is less toxic than BuCy2 and our results did not suggest that in high-risk AML, BuCy2 should be the favorite regimen in terms of efficacy." @default.
• W2141561613 created "2016-06-24" @default.
• W2141561613 creator A5001406717 @default.
• W2141561613 creator A5013001610 @default.
• W2141561613 creator A5025721904 @default.
• W2141561613 creator A5030847447 @default.
• W2141561613 creator A5032955393 @default.
• W2141561613 creator A5043145355 @default.
• W2141561613 creator A5051391019 @default.
• W2141561613 creator A5061896020 @default.
• W2141561613 creator A5067216825 @default.
• W2141561613 creator A5076652491 @default.
• W2141561613 creator A5079652136 @default.
• W2141561613 creator A5083514231 @default.
• W2141561613 creator A5086056369 @default.
• W2141561613 creator A5086116060 @default.
• W2141561613 creator A5088506587 @default.
• W2141561613 date "2014-12-01" @default.
• W2141561613 modified "2023-10-14" @default.
• W2141561613 title "Tolerability and Efficacy of Busulfan and Fludarabine As Allogeneic Pretransplant Conditioning Therapy in Acute Myeloid Leukemia: Comparison With Busulfan and Cyclophosphamide Regimen" @default.
• W2141561613 cites W1565345042 @default.
• W2141561613 cites W1905059524 @default.
• W2141561613 cites W1972172571 @default.
• W2141561613 cites W1989320328 @default.
• W2141561613 cites W1990247501 @default.
• W2141561613 cites W1992090010 @default.
• W2141561613 cites W199387403 @default.
• W2141561613 cites W1996119718 @default.
• W2141561613 cites W2001502135 @default.
• W2141561613 cites W2013051826 @default.
• W2141561613 cites W2018956546 @default.
• W2141561613 cites W2024390130 @default.
• W2141561613 cites W2027703570 @default.
• W2141561613 cites W2032883855 @default.
• W2141561613 cites W2037210819 @default.
• W2141561613 cites W2038204317 @default.
• W2141561613 cites W2038424578 @default.
• W2141561613 cites W2040886821 @default.
• W2141561613 cites W2042814209 @default.
• W2141561613 cites W2042888665 @default.
• W2141561613 cites W2057508074 @default.
• W2141561613 cites W2059706629 @default.
• W2141561613 cites W2071539684 @default.
• W2141561613 cites W2088346020 @default.
• W2141561613 cites W2094729406 @default.
• W2141561613 cites W2116858301 @default.
• W2141561613 cites W2135329608 @default.
• W2141561613 cites W2150509524 @default.
• W2141561613 cites W2162927689 @default.
• W2141561613 cites W2166858780 @default.
• W2141561613 cites W2328305239 @default.
• W2141561613 cites W2339482838 @default.
• W2141561613 cites W2618073389 @default.
• W2141561613 cites W4246085869 @default.
• W2141561613 doi "https://doi.org/10.1016/j.clml.2014.04.006" @default.
• W2141561613 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25034142" @default.
• W2141561613 hasPublicationYear "2014" @default.
• W2141561613 type Work @default.
• W2141561613 sameAs 2141561613 @default.
• W2141561613 citedByCount "7" @default.
• W2141561613 countsByYear W21415616132015 @default.
• W2141561613 countsByYear W21415616132018 @default.
• W2141561613 countsByYear W21415616132020 @default.
• W2141561613 countsByYear W21415616132021 @default.
• W2141561613 countsByYear W21415616132022 @default.
• W2141561613 countsByYear W21415616132023 @default.
• W2141561613 crossrefType "journal-article" @default.
• W2141561613 hasAuthorship W2141561613A5001406717 @default.
• W2141561613 hasAuthorship W2141561613A5013001610 @default.
• W2141561613 hasAuthorship W2141561613A5025721904 @default.
• W2141561613 hasAuthorship W2141561613A5030847447 @default.
• W2141561613 hasAuthorship W2141561613A5032955393 @default.
• W2141561613 hasAuthorship W2141561613A5043145355 @default.
• W2141561613 hasAuthorship W2141561613A5051391019 @default.
• W2141561613 hasAuthorship W2141561613A5061896020 @default.
• W2141561613 hasAuthorship W2141561613A5067216825 @default.
• W2141561613 hasAuthorship W2141561613A5076652491 @default.
• W2141561613 hasAuthorship W2141561613A5079652136 @default.
• W2141561613 hasAuthorship W2141561613A5083514231 @default.
• W2141561613 hasAuthorship W2141561613A5086056369 @default.
• W2141561613 hasAuthorship W2141561613A5086116060 @default.
• W2141561613 hasAuthorship W2141561613A5088506587 @default.
• W2141561613 hasConcept C126322002 @default.
• W2141561613 hasConcept C141071460 @default.
• W2141561613 hasConcept C197934379 @default.
• W2141561613 hasConcept C203014093 @default.
• W2141561613 hasConcept C2776694085 @default.
• W2141561613 hasConcept C2776755627 @default.
• W2141561613 hasConcept C2776863199 @default.
• W2141561613 hasConcept C2777408962 @default.
• W2141561613 hasConcept C2778375690 @default.
• W2141561613 hasConcept C2778461978 @default.
• W2141561613 hasConcept C2778729363 @default.
• W2141561613 hasConcept C2779263901 @default.
• W2141561613 hasConcept C2780611847 @default.
• W2141561613 hasConcept C2781413609 @default.
• W2141561613 hasConcept C2908647359 @default.
• W2141561613 hasConcept C2911091166 @default.

• next